A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing

Journal of Thoracic Oncology

Volumn 11, Issue 11, 2016, Pages 1846-1855

  Matter Walstra, Klazien ^a,b   Schwenkglenks, Matthias ^b   Aebi, Stefan ^a,c   Dedes, Konstantin ^d   Diebold, Joachim ^e   Pietrini, Mario ^c   Klingbiel, Dirk ^a   Von Moos, Roger ^a,f   Gautschi, Oliver ^a,c  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c LUZERNER KANTONSSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Pathologische Institut am Kantonsspital Luzern   (Switzerland)

^f KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Costeffectiveness; Docetaxel; ICER; Lung cancer; Nivolumab; QALY

Indexed keywords

DOCETAXEL; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID;

ADVANCED CANCER; ALOPECIA; ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT DURATION; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; LUNG NEOPLASMS; MALE; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUALITY-ADJUSTED LIFE YEARS; TAXOIDS;

EID: 84995921598     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.032     Document Type: Article

References (46)

1. Hashim D, Boffetta P, La Vecchia C, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016;27:226-933.
2. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488-3515.
3. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii27-iii39.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
5. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981-988.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
7. Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014;32:1902-1908.
8. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeco-nomics. 2004;22:581-589.
9. Shah M, Winfree KB, Peterson P, et al. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with non-squamous non-small cell lung cancer in the US outpatient setting. Lung Cancer. 2013;82:121-127.
10. Matter-Walstra K, Joerger M, Kuhnel U, et al. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health. 2012;15:65-71.
11. Borget I, Cadranel J, Pignon JP, et al. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Eur Respir J. 2012;39:172-179.
12. Brown T, Pilkington G, Bagust A, et al. Clinical effectiveness and cost-effectiveness of first-line chemo-therapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2013;17:1-278.
13. Greenhalgh J, Bagust A, Boland A, et al. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technol Assess. 2015;19:1-134.
14. Melosky B, Chu Q, Juergens R, et al. Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol. 2016;34:1676-1688.
15. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
16. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
17. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
18. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10:e0130142.
19. BAG. Bundesamt für Gesundheit Spezialitätenliste. http://bag.e-mediat.net/SL2007.Web.External/. Accessed January 25, 2016.
20. Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2016;2:19-21.
21. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol. 2015;26:1547-1573.
22. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563-2577.
23. National Institute for Health and Care Excellence. Nivolumab for previously treated locally advanced or metastatic squamous nonsmall-cell lung cancer. https://s3.amazonaws.com/assets.fiercemarkets.net/public/005-LifeSciences/niceopdivoappraisal.pdf. Accessed Feb 29, 2016.
24. Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modelling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016:1-33.
25. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27: 147-153.
26. Joerger M, Matter-Walstra K, Fruh M, et al. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol. 2011;22:567-574.
27. Matter-Walstra K, Braun R, Kolb C, et al. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting. Br J Dermatol. 2015;163: 1462-1470.
28. Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res. 2010;38:9-21.
29. EuroQol Group Association. EQ-5-D. About EQ-5D. http://www.euroqol.org. Accessed January 25, 2016.
30. TARMED Suisse. Tarifversion: 1.08. http://www.tarmed suisse.ch/offline-browser.html. Accessed January 25, 2016.
31. Swiss DRG. www.swissdrg.org. Accessed January 25, 2016.
32. Brandle M, Goodall G, Erny-Albrecht KM, et al. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly. 2009;139:173-184.
33. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality- A djusted life year: in search of a standard. Med Decis Making. 2000;20:332-342.
34. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
35. Kantarjian H, Steensma D, Rius Sanjuan J, et al. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10:e208-e211.
36. Howard DH, Bach PB, Berndt ER, et al. Pricing in the market for anticancer drugs. JEP. 2015;29:139-162.
37. Peters S, von Moos R, Thurlimann B. [Is prescription of a therapy costing 150, 000 CHF reasonable?]. Rev Med Suisse. 2015;11:1967-1972 [in German].
38. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
39. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634-642.
40. Matter-Walstra K, Braun R, Kolb C, et al. Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. Br J Dermatol. 2016;174:463.
41. Sebaratnam DF, Anforth R, Fernandez-Penas P. Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanoma. Br J Dermatol. 2016;174:462-463.
42. Biller-Andorno N, Zeltner T. Individual responsibility and community solidarity-the Swiss health care system. N Engl J Med. 2015;373:2193-2197.
43. Cerny D, Cerny T, Ess S, et al. Lung cancer in the Canton of St. Gallen, Eastern Switzerland: sex- A ssociated differences in smoking habits, disease presentation and survival. Onkologie. 2009;32:569-573.
44. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375-2391.
45. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizu-mab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.
46. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14:255-264.